Novartis (NYSE:NVS), the Swiss pharmaceutical leader, said on Friday that the newly introduced 100% U.S. tariff on branded drugs “should have no impact” on its business.
The company emphasized that its $23 billion investment in American infrastructure, along with the rollout of new production sites across the country, helps shield operations from potential consequences of the measure.
“We are working to ensure that all major Novartis medicines for U.S. patients are manufactured in the U.S.,” the company said in a statement. “Against this backdrop, the announced 100% tariff should have no impact on Novartis.”
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.